source
- Anti-aging biotech NewLimit raises $435M at $3B+ valuationThe Bay Area startup NewLimit has closed one of biotech's largest private financings of 2026 and expects to start human testing next year for its first anti-aging drug candidate. NewLimit said Tues…Endpoints · 1mo ago↗ source
- STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trialLongevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.STAT · 1mo ago↗ source
- What’s next for VEGF? #ASCO26 offered clues, but answers will have to waitCHICAGO — Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses. Many ...